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Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with 
methylphosphonate groups) that might be labeled with 188Re and 99mTc presents a strong 
potential for metabolic radiotherapy and diagnosis, respectively. The aim of this study was to 
evaluate in vivo the potential of 188Re-PEI-MP as therapeutic agent for bladder carcinoma and 
99mTc-PEI-MP for its diagnosis and follow up.  
Material and Methods: Cytotoxicity of PEI-MP was investigated in bladder carcinoma cell line 
(CRL-1472) using the MTT test for different concentrations of PEI-MP (1 µM to 1000 µM) and 
incubation times (24h, 48h, 72h and 96h). Radiochemical purity of 99mTc-PEI-MP and 188Re-PEI-
MP was achieved using ascending microchromatography. For the in vivo studies six groups of 
Balb/c nu/nu mice were used: four normal groups injected with Na99mTcO4 (n=10), 99mTc-PEI-MP 
(n=10), Na188ReO4 (n=18) and 188Re-PEI-MP (n=17), respectively; two with bladder carcinoma 
xenotransplants injected with Na188ReO4 (n=8) and 188Re-PEI-MP (n=12), respectively. When the 
tumors reached the appropriate volume, radiopharmaceuticals were administered by an 
intravenous injection in the tail vein (22-37MBq), with the animal anesthetized and previously 
 
  
  
  
 
 
 
 
 
placed on the gamma camera detector. Immediately, a dynamic acquisition followed, with a 
128x128 matrix for 10 min (20 frames, 30 seconds). Static images (2 min) were performed with a 
256x256 matrix, where each of the six groups was divided into two groups, of which one was 
imaged at 120 minutes, and the other at 240 minutes. For biodistribution proposes, mice were 
euthanized 2 and 4 hours after injection and organ samples were weighted and counted in a well-
counter to obtain percentage injected activity per gram of organ (%ID/g).  
Results and Discussion: The MTT assay showed that PEI-MP is not cytotoxic. The 
radiochemical purity of 188Re-PEI-MP and 99mTc-PEI-MP was ≥85%. Biodistribution results, with 
Na188ReO4 and Na99mTcO4, showed a higher uptake by the thyroid, bladder and stomach, 
following a normal biodistribution. The biodistribution with 188Re-PEI-MP and 99mTc-PEI-MP 
showed that the excretion of these complexes occurs primarily through the renal system, with a 
small fraction being eliminated by the hepatobiliary system. Tumor/muscle ratio for 188Re-PEI-MP 
was greater than 1.5. 
Conclusions: Given its biodistribution and tumor/muscle ratio, 188Re-PEI-MP seems to be 
promising in the treatment of bladder cancer. Following the same biodistribution as 188Re-PEI-
MP, 99mTc-PEI-MP seems to be optimal for diagnosis and follow up of therapy. 
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